Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06630624
Title Dose Finding, Efficacy and Immunological Response of IP-001 Following RFA, MWA or IRE for CRLM (INJECTABL-II)
Acronym INJECTABL-II
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.R. Meijerink
Indications
Therapies
Age Groups: senior | adult
Covered Countries NLD


No variant requirements are available.